Viewing Study NCT06189495

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:35 PM
Ignite Modification Date: 2026-02-03 @ 12:50 PM
Study NCT ID: NCT06189495
Status: RECRUITING
Last Update Posted: 2025-01-17
First Post: 2023-11-13
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Systemic Sclerosis Associated Interstitial Lung Disease View
None Rheumatoid Arthritis Associated Interstitial Lung Disease (RA-ILD) View
None Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None connective tissue disease-associated interstitial lung disease View
None Rheumatoid Arthritis associated Interstitial Lung Disease (RA-ILD) View
None Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) View